JSM Activity #213

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2002 Program page


Activity ID:  213
Title
* Data Analysis in Clinical Trials
Date / Time / Room Sponsor Type
08/13/2002
10:30 AM - 12:20 PM
Room: H-Gibson Suite 		Biometrics Section*, Biopharmaceutical Section*, ENAR Contributed
Organizer: n/a
Chair: Alan D. Weinberg, Columbia University
Discussant:  
Description

Analysis of the primary endpoint by intention-to-treat is usually a simple matter. Yet clinical trials often collect other forms of data whose analysis is not so straightforward. These talks will give examples of some current challenges to analysis of clinical trial data: causal inference, subgrouping, adverse events, genetic data, and data with excess zeros.
  300516  By:  Michele L. Shaffer 10:35 AM 08/13/2002
Using Counterfactuals to Account for Treatment Failures in Clinical Trials

  301850  By:  Heather R. Crosby 10:50 AM 08/13/2002
An Efficient Method of Subgrouping in Crossover Trials and its Performance Evaluation by Simulations

  300880  By:  Tailiang  Xie 11:05 AM 08/13/2002
Statistical Analysis of Complicated Adverse Event Data in Clinical Trials

  300454  By:  Jitendra   Ganju 11:20 AM 08/13/2002
Resolving a Controversy Cver Weighted Versus Unweighted Means

  301793  By:  Shou-En  Lu 11:35 AM 08/13/2002
Analyzing Excessive No Changes in Clinical Trials with Clustered Data

  301321  By:  Samuel  Wieand 11:50 AM 08/13/2002
Looking for Treatment Effect in Genetic Sub-studies of Randomized Trials: Do We Need to Genotype Controls?

  300676  By:  Barry R. Davis 12:05 PM 08/13/2002
Gene-drug Interactions in the Context of an Active-Control Trial

JSM 2002

For information, contact meetings@amstat.org or phone (703) 684-1221.

If you have questions about the Continuing Education program, please contact the Education Department.

Revised March 2002